院外心脏骤停终止复苏规则的成本效果分析
本研究基于日本2019年1月1日至12月31日全国性院外心脏骤停登记(126,271例,57.3%男性,中位年龄80岁)及已发表数据,构建决策树与Markov联合模型,从医疗支付方角度比较基础生命支持终止复苏规则(BLS规则)、高级生命支持终止复苏规则(ALS规则)和无终止复苏规则三种场景的终身成本与质量调整生命年(QALY)。BLS规则场景成本更低且QALY更少;以BLS规则为参照,ALS规则场景和无规则场景的增量成本效果比(ICER)分别为81,000和98,762美元/QALY。在日本支付意愿阈值500万日元(45,455美元)下,BLS规则场景在100%模拟中具成本效果;ALS规则场景和无规则场景需支付阈值分别高于80,000和204,000美元才具成本效果。结论认为无规则场景在可接受支付阈值内不具成本效果,需进一步开展终止复苏规则的健康经济学研究。
要点
- 以BLS规则场景为参照,ALS规则场景的ICER为81,000美元/QALY,无规则场景的ICER为98,762美元/QALY。
- BLS规则场景在日本支付意愿阈值500万日元(45,455美元)下,100%模拟中具成本效果。
- ALS规则场景需支付阈值高于80,000美元、无规则场景需高于204,000美元才具成本效果。
- 无规则场景在可接受支付阈值内不具成本效果。
适用人群与场景
- 日本全国性院外心脏骤停登记中2019年1月1日至12月31日的患者,共126,271例,57.3%为男性,中位年龄80岁。
研究设计与关键结果
- 研究类型为基于全国性人群登记和已发表数据的成本效果分析模型(决策树与Markov联合模型),从医疗支付方角度比较三种场景。
- 登记纳入126,271例院外心脏骤停患者,57.3%为男性,中位年龄80岁。
- BLS规则场景的成本低于ALS规则场景和无规则场景,QALY也少于后两者。
- 以BLS规则场景为参照,ALS规则场景的ICER为81,000美元/QALY,无规则场景的ICER为98,762美元/QALY。
- 在日本支付意愿阈值500万日元(45,455美元)下,BLS规则场景在100%模拟中具成本效果。
- ALS规则场景需支付阈值高于80,000美元、无规则场景需高于204,000美元才具成本效果。
证据类型、等级与局限
- 证据类型:基于全国性登记的成本效果分析模型研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在可接受支付阈值内,无规则场景与BLS规则场景相比不具成本效果。
- 作者认为,需进一步开展终止复苏规则的健康经济学研究,以支持实施终止复苏规则的建设性讨论。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To evaluate the cost-effectiveness of practices with and without termination-of-resuscitation (TOR) rules for out-of-hospital cardiac arrest (OHCA), using an analytic model based on a nationwide population-based registry in Japan.
METHODS: A combined model using a decision tree and Markov model was developed to compare costs and treatment effectiveness of three scenarios: basic life support (BLS) TOR rules (BLS-rule scenario), advanced life support (ALS) TOR rules (ALS-rule scenario), and no TOR rules (No-rule scenario). A nationwide population-based OHCA registry from January 1 to December 31, 2019 and published data were used. Analyses were performed from healthcare payers' perspectives. Life-time incremental cost-effectiveness ratio (ICER) was determined by the difference in cost between two scenarios, divided by the difference in quality adjusted life year (QALY).
RESULTS: The OHCA registry included 126,271 patients (57.3% men; median age, 80 years). The BLS-rule scenario yielded lower cost and less QALY than the ALS-rule scenario and No-rule scenario. With reference to the BLS-rule scenario, the ICERs for the ALS-rule scenario and No-rule scenario were 81,000 and 98,762 USD per QALY, respectively. The BLS-rule scenario was cost-effective in 100% of simulations at the willingness-to-pay threshold in Japan (5 million JPY = 45,455 USD). The willingness-to-pay threshold higher than 80,000 and 204,000 USD were required for the ALS-rule scenario and No-rule scenarios, respectively, to be cost-effective.
CONCLUSION: No-rule scenario was not cost-effective compared with BLS-rule scenario within acceptable willingness-to-pay thresholds. Further research on health economics of TOR rules is warranted to support constructive discussion on implementing TOR rules.
参考来源
- Shibahashi K, Konishi T, Ohbe H, et al. Cost-effectiveness analysis of termination-of-resuscitation rules for patients with out-of-hospital cardiac arrest. Resuscitation. 2022. PMID: 36176229. doi:10.1016/j.resuscitation.2022.09.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。